This is a fixed-combination gummy formulation containing sildenafil and tadalafil, both PDE5 inhibitors. The combination is studied for its role in PDE5 inhibition and the associated vascular and cGMP-related signaling pathways.

This gummy formulation is used in controlled laboratory workflows and in-vitro systems examining PDE5 activity, vascular signaling, and smooth-muscle regulation. It is applied in structured research models characterizing compound activity and downstream pathway interactions.

The combination supports analytical studies and cell-based models involving PDE5 inhibition, nitric-oxide and cGMP signaling, blood-flow regulation, and vascular smooth-muscle mechanisms. It is relevant for pathway characterization and assay development focused on vascular mechanisms within controlled study frameworks.

This combination gummy is suited for researchers and investigators studying dual PDE5 inhibition and related vascular and cGMP signaling mechanisms within controlled study frameworks.